For more than fifteen years, scientists have suspected that a toxin made by a common gut bacterium, Bacteroides fragilis, helps set the stage for colorectal cancer — but they could not explain how the toxin reached the cells it harmed. A new study from the Johns Hopkins Kimmel Cancer Center finally names the molecular doorway, and in doing so opens a plausible route to stopping it.
The toxin, called BFT, does not wander blindly. The team showed it must first latch onto a host protein called claudin-4, a component of the seals between colon cells, before it can injure those cells. Claudin-4 normally helps keep the gut barrier tight; by hijacking it, the toxin gains a foothold that lets it do damage deeper in the tissue. The work, published in Nature, was led by the Bloomberg~Kimmel Institute for Cancer Immunotherapy with support from the National Institutes of Health.
Senior author Cynthia Sears, M.D., described the moment as exciting after several failed attempts to identify the receptor. Understanding how bacterial toxins physically enter colon cells, she noted, can open doors to new ways of detecting and treating associated diseases — including diarrhea, colorectal cancer, and bloodstream infections.
The discovery has already inspired a blocking strategy. If the toxin needs claudin-4 to get in, then interfering with that handshake could neutralize it. Early work suggests candidate molecules that disrupt the binding, though they are far from a finished therapy. The broader lesson is that some of the microbes we carry harmlessly in small numbers may, under the right conditions, exploit specific cellular entry points to nudge tissue toward disease.
Knowledge takeaway: the gut bacterium Bacteroides fragilis releases a toxin (BFT) that causes colon damage only after binding the host protein claudin-4, the linchpin of the gut barrier; identifying this receptor solves a 15-year puzzle and suggests a new class of blockers that could prevent toxin-driven colorectal cancer at its entry point.